Anzeige
Mehr »
Login
Freitag, 01.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
200.000 Unzen pro Jahr: Die Goldaktie, die kurz davor steht, Geschichte zu schreiben
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
497 Leser
Artikel bewerten:
(2)

Gilead Sciences: Latinas Contra Cancer Empowers Patients To Advocate for Change

NORTHAMPTON, MA / ACCESSWIRE / December 15, 2022 / When Darcie Green's dad got sick, she thought she was prepared to help him navigate the healthcare system. She'd spent her entire career in healthcare policy. But as he got sicker and his care got more complicated, she found herself in over her head.

"Even with all of the knowledge I had of healthcare policy, and all of the working knowledge I had of patient advocacy in healthcare systems, it was so difficult for my dad to get adequate care," remembers Darcie. "I was faced with this very personal and scary moment of seeing firsthand unnecessary issues within healthcare systems."

Darcie's dad eventually recovered, but the experience of fighting for his care had a big impact on her. Today, she brings that unique perspective into her daily work, as the Executive Director of Latinas Contra Cancer, a San Jose-based nonprofit advocacy organization and Gilead grantee.

Latinas Contra Cancer nonprofit
Founded in 2003, Latinas Contra Cancer aims to raise awareness about cancer in the Latinx community and advocate for improved care. Through its support groups, skilled patient advocates and educational programs, the organization has improved the health outcomes of thousands of individuals in Santa Clara and San Mateo counties in the Bay Area as they navigate cancer diagnoses and treatment.

Darcie came on as Executive Director four years ago, but she was well aware of the organization's mission for a long time: Before passing away from breast cancer, Darcie's grandmother who lived in San Jose was in the very first support group held by Latinas Contra Cancer. "I know just how important getting linguistically and culturally competent support during her cancer journey was for my grandmother," says Darcie. "She received dignity and care from the organization."

In the four years since Darcie started at the organization, she's helped strengthen its programs, expand its support groups and rebrand its patient advocacy division - all rooted in the Latinx community.

"If someone diagnosed with cancer is having an issue with getting the follow-up screenings that they need or the quality care that they deserve, we make sure they don't have to navigate through it alone," she says.

Providing support for people who come through Latinas Contra Cancer remains at the core of its mission. But as Darcie dove further into the work, she began to identify the many racial and ethnic disparities in care.

"We're helping people navigate care each day by assisting them in getting to their appointments and getting better treatment," she says. "But it's not eliminating these injustices from happening. We're just helping people navigate them."

Defensoras: Healthcare Advocate Training program
To make a difference in these efforts, Latinas Contra Cancer launched Defensoras: Healthcare Advocate Training, a program for patients that's designed with modules on topics such as patient's rights, healthcare justice and navigating treatment options. Graduates of the 10-week program have the potential to generate significant improvements in their healthcare community. But as cancer survivors themselves, there's an added layer of importance to the work.

"This is really about power building in the Latinx patient population to push healthcare systems to be more just," says Darcie. "It's a big win for everybody because when patients feel more powerful, they have more hope. Adjusting the power dynamic between patients and healthcare providers is important to us."

By arming these patients with the tools they need to create change, Darcie is working to expand the reach of Latinas Contra Cancer.

"We're going to have large numbers of patients with more knowledge of policy and the healthcare system and how to prevent disparities," says Darcie. "This additional knowledge will help us identify what we should take on next."

Originally published by Gilead Sciences https://stories.gilead.com/articles/latinas-contra-cancer-empowers-patients-to-advocate-for-change

Gilead Sciences, Thursday, December 15, 2022, Press release picture

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: http://www.gilead.com/
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View source version on accesswire.com:
https://www.accesswire.com/731987/Gilead-Sciences-Latinas-Contra-Cancer-Empowers-Patients-To-Advocate-for-Change

© 2022 ACCESSWIRE
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.